Gland Pharma Limited has fulfilled its quarterly regulatory compliance by submitting a certificate under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026.

Regulatory Compliance Details

The pharmaceutical company submitted the mandatory certificate to both BSE Limited and National Stock Exchange of India Limited on April 13, 2026. The submission was made by Sampath Kumar Pallerlamudi, Company Secretary & Compliance Officer, ensuring adherence to regulatory timelines.

Certificate Confirmation

The confirmation certificate was issued by MUFG Intime India Private Limited, formerly known as Link Intime India Private Limited, which serves as the company's Registrar and Share Transfer Agent. Ashok Shetty, Sr. Vice President – Corporate Registry at MUFG Intime, signed the certificate confirming compliance with regulatory requirements.

Key Regulatory Statement

The certificate specifically confirms that no requests for dematerialization or rematerialization of equity shares were received during the quarter ended March 31, 2026. This confirmation is mandated under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, which requires periodic reporting of share transfer activities.

Corporate Information

Gland Pharma Limited maintains its registered office at Survey No. 143-148, 150 & 151, Near Gandimaisamma 'X' Roads, D.P. Pally, Dundigal, in Medchal-Malkajgiri District, Hyderabad. The company's corporate office is located at Plot No. 11 & 84, TSIIC Phase IV, Pashamylaram, Patancheru, Sangareddy District, Hyderabad. This quarterly submission demonstrates the company's commitment to maintaining transparent regulatory compliance and proper corporate governance practices in accordance with SEBI guidelines.

Gland Pharma Limited has strengthened its senior management team with the appointment of Mr. Prasadha Rao Lysetti as Senior Vice-President (Head - Operations), effective April 06, 2026. The pharmaceutical company announced this key leadership addition in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Key Appointment Details

The appointment represents a strategic addition to Gland Pharma's operations leadership, with Mr. Lysetti assuming the role of Senior Management Personnel within the organization.

Professional Background and Expertise

Mr. Prasadha Rao Lysetti brings extensive pharmaceutical industry experience to his new role at Gland Pharma. His professional profile demonstrates significant expertise in pharmaceutical manufacturing and operations management.

Experience and Specialization

• Industry Experience: 25+ years of progressive expertise
• Core Competencies: Managing complex formulations and large-scale pharmaceutical manufacturing
• Operational Focus: Quality-centric operations and operational efficiency enhancement
• Leadership Areas: Lean and operational excellence initiatives
• Global Exposure: Experience across diverse cultures and global locations

Career History

Prior to joining Gland Pharma, Mr. Lysetti held positions at several prominent pharmaceutical organizations:

• Cronus Pharma India Private Limited (Rising Pharmaceuticals Group)
• Vitema Pharmaceuticals
• Eugia Pharma Specialities Limited
• Dr. Reddy's Laboratories Limited
• Glenmark Generics Ltd
• Pharma Care FZE LLC

Educational Qualifications and Certifications

Mr. Lysetti's educational background reflects his commitment to continuous learning and professional development:

Strategic Significance

The appointment of Mr. Lysetti as Senior Vice-President (Head - Operations) aligns with Gland Pharma's focus on operational excellence and manufacturing efficiency. His extensive experience in pharmaceutical operations and proven track record in quality management and operational improvements position him to contribute significantly to the company's operational objectives.

The company has fulfilled all disclosure requirements under SEBI regulations, providing comprehensive details about the appointment in accordance with regulatory guidelines.